Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 6:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 563 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: PCI Clear all
Terminated Phase 4 Interventional

A Trial Evaluating the Efficacy and Safety of Tenecteplase Together With Unfractionated Heparin Prior to Early Percutaneous Coronary Intervention (PCI) as Compared to Standard Primary PCI in Patients With Acute Myocardial Infarction (ASSENT 4 PCI)

NCT00168792
View directory record Official record
Conditions
Myocardial Infarction
Interventions
Tenecteplase, PCI
Drug · Procedure
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
1,671 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
8
States / cities
Little Rock, Arkansas • Fort Lauderdale, Florida • St. Petersburg, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2013 · Synced Oct 24, 2026, 6:21 PM EDT
Terminated Phase 4 Interventional

Angiomax® or Unfractionated Heparin for Patients Undergoing Percutaneous Coronary Intervention

NCT01464671
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Bivalirudin, Heparin
Drug
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Nov 20, 2014 · Synced Oct 24, 2026, 6:21 PM EDT
Completed Phase 4 Interventional

Counterpulsation Reduces Infarct Size Pre-PCI for AMI

NCT00833612
View directory record Official record
Conditions
Acute Myocardial Infarction (AMI)
Interventions
Counterpulsation with IAB
Device
Lead sponsor
Datascope Corp.
Industry
Eligibility
18 Years to 90 Years
Enrollment
339 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
16
States / cities
Birmingham, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2011 · Synced Oct 24, 2026, 6:21 PM EDT
Terminated Not applicable Interventional

OPTIMIZE IDE for the Treatment of ACS

NCT03190473
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
DES
Device
Lead sponsor
Svelte Medical Systems, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
54
States / cities
Fairhope, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 46 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2023 · Synced Oct 24, 2026, 6:21 PM EDT
Terminated Phase 3 Interventional Results available

Effect of Lantus and Apidra in Patients With Acute ST Elevation Myocardial Infarction

NCT00670228
View directory record Official record
Conditions
AMI
Interventions
Insulin Glargine (LANTUS), Insulin Glulisine (Apidra), Standard Therapy
Drug
Lead sponsor
Sanofi
Industry
Eligibility
35 Years to 80 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 11, 2011 · Synced Oct 24, 2026, 6:21 PM EDT
Completed No phase listed Observational

Cardiovascular Patient Outcomes and Research Team Primary PCI Registry

NCT02201264
View directory record Official record
Conditions
ST Elevation Myocardial Infarction
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
6,726 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
14
States / cities
Bryan, Ohio • Chardon, Ohio • Columbus, Ohio + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2018 · Synced Oct 24, 2026, 6:21 PM EDT
Completed Phase 1Phase 2 Interventional

Study of the Effect of Aerosolized, Recombinant Alpha 1-Antitrypsin on Epithelial Lining Fluid Analytes in Subjects With Alpha 1-Antitrypsin Deficiency

NCT00157092
View directory record Official record
Conditions
Alpha1-antitrypsin Deficiency
Interventions
Aerosolized, Recombinant Alpha 1-Antitrypsin
Drug
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated May 5, 2021 · Synced Oct 24, 2026, 6:21 PM EDT
Terminated Phase 2 Interventional Results available

Ranolazine Cardioprotection in PCI

NCT01767987
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Harvey Hahn
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Kettering, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 14, 2017 · Synced Oct 24, 2026, 6:21 PM EDT
Active, not recruiting Not applicable Interventional

Impella®-Supported PCI in High-Risk Patients With Complex Coronary Artery Disease and Reduced Left Ventricular Function

NCT04763200
View directory record Official record
Conditions
Left Ventricular Dysfunction, Coronary Artery Disease
Interventions
Impella CP® / Impella CP® with SmartAssist® / Impella 2.5®, IABP Intra-aortic balloon pump
Device
Lead sponsor
Abiomed Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
1,252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
83
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 24, 2026, 6:21 PM EDT
Completed No phase listed Observational

Angio-Seal Evolution Device Registry

NCT00817349
View directory record Official record
Conditions
Peripheral Vascular Disease, Coronary Artery Disease, Peripheral Artery Disease, Arterial Occlusive Disease, Coronary Heart Disease
Interventions
Not listed
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
1,004 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
10
States / cities
Los Angeles, California • Ypsilanti, Michigan • Camden, New Jersey + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2019 · Synced Oct 24, 2026, 6:21 PM EDT
Withdrawn Not applicable Interventional

Pharmacodynamic Study on Efficacy of Clopidogrel With St. John's Wort

NCT01330589
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Placebo, St. Johns Wort
Drug
Lead sponsor
Lancaster General Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Lancaster, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Oct 24, 2026, 6:21 PM EDT
Not listed No phase listed Observational

Prevalence and Level of Thienopyridine Resistance Seen in a Contemporary Percutaneous Coronary Intervention or Coronary Artery Bypass Graft Population

NCT01408927
View directory record Official record
Conditions
Increased Drug Resistance
Interventions
Thienopyridine resistance testing, Aspirin resistance testing, Genetic polymorphism assessment
Other
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 11, 2014 · Synced Oct 24, 2026, 6:21 PM EDT
Recruiting Not applicable Interventional

Coronary Computed Tomography Angiography (CCTA) for the Pre-procedural Planning of Percutaneous Coronary Intervention

NCT07691502
View directory record Official record
Conditions
Coronary Artery Disease, CT
Interventions
CT-guided PCI, Routine PCI
Procedure
Lead sponsor
Minneapolis Heart Institute Foundation
Other
Eligibility
22 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 24, 2026, 6:21 PM EDT
Not listed No phase listed Observational

FFR vs. icECG in Coronary Bifurcations

NCT01724957
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Intracoronary ECG
Procedure
Lead sponsor
University National Heart Hospital
Other
Eligibility
18 Years to 90 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 20, 2019 · Synced Oct 24, 2026, 6:21 PM EDT
Completed Phase 1 Interventional

Randomized Evaluation of Intracoronary Transplantation of Bone Marrow Stem Cells in Myocardial Infarction

NCT00874354
View directory record Official record
Conditions
Myocardial Infarction
Interventions
Intracoronary Transplantation of Bone Marrow Stem Cells
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 2, 2017 · Synced Oct 24, 2026, 6:21 PM EDT
Completed Phase 2 Interventional Results available

Ticagrelor and Eptifibatide Bolus-Only Versus Ticagrelor and Eptifibatide Bolus Plus Abbreviated Infusion

NCT01919723
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Ticagrelor, Eptifibatide
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
Birmingham, Alabama • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Oct 24, 2026, 6:21 PM EDT
Completed Not applicable Interventional Results available

HARMONEE - Japan-USA Harmonized Assessment by Randomized, Multi-Center Study of OrbusNEich's Combo StEnt

NCT02073565
View directory record Official record
Conditions
Coronary Arteriosclerosis, Non ST Segment Elevation Acute Coronary Syndrome
Interventions
OrbusNeich Combo stent™, Everolimus Eluting Stent (EES)
Device
Lead sponsor
OrbusNeich
Industry
Eligibility
20 Years and older
Enrollment
572 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
17
States / cities
Washington D.C., District of Columbia • Lake Worth, Florida • Miami, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated May 13, 2022 · Synced Oct 24, 2026, 6:21 PM EDT
Completed Phase 4 Interventional

Scripps Evaluation of Antiplatelet Therapies for Intermediate Duration With the Endeavor Stent (Seaside)

NCT00963781
View directory record Official record
Conditions
Coronary Artery Disease, Coronary Thrombosis
Interventions
Medtronic Endeavor Stent, Reduced duration (6 months) DAPT
Device · Drug
Lead sponsor
Scripps Health
Other
Eligibility
18 Years and older
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Oct 20, 2020 · Synced Oct 24, 2026, 6:21 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate Efficacy and Safety of VX-864 in Participants With the PiZZ Genotype

NCT05643495
View directory record Official record
Conditions
Alpha-1 Antitrypsin Deficiency
Interventions
VX-864
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
10
States / cities
Gainesville, Florida • Orlando, Florida • Iowa City, Iowa + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Oct 24, 2026, 6:21 PM EDT
Recruiting Phase 4 Interventional

Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention

NCT06909565
View directory record Official record
Conditions
Percutaneous Coronary Intervention, Peripheral Endovascular Intervention
Interventions
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, Normal Saline (Placebo)
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
6,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
147
States / cities
Alexander City, Alabama • Birmingham, Alabama • Huntsville, Alabama + 130 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 24, 2026, 6:21 PM EDT
Recruiting Not applicable Interventional

Prevail Global Study

NCT06535854
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Prevail DCB, Agent DCB
Device
Lead sponsor
Medtronic Vascular
Industry
Eligibility
18 Years and older
Enrollment
1,205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
55
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tucson, Arizona + 48 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 24, 2026, 6:21 PM EDT
Completed Not applicable Interventional Results available

International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA)

NCT01471522
View directory record Official record
Conditions
Cardiovascular Diseases, Coronary Disease, Coronary Artery Disease, Heart Diseases, Myocardial Ischemia
Interventions
cardiac catheterization, coronary artery bypass graft surgery, percutaneous coronary intervention, Lifestyle, Medication
Procedure · Behavioral · Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
21 Years and older
Enrollment
5,179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2023
U.S. locations
109
States / cities
Birmingham, Alabama • Yuma, Arizona • Beverly Hills, California + 82 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2023 · Synced Oct 24, 2026, 6:21 PM EDT
Completed No phase listed Observational

The Use of High Resolution Chest Computed Tomography in Alpha-1 Antitrypsin Deficiency

NCT00532805
View directory record Official record
Conditions
Alpha-1 Antitrypsin Deficiency
Interventions
Not listed
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
7
States / cities
Denver, Colorado • Gainesville, Florida • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 24, 2026, 6:21 PM EDT
Active, not recruiting Phase 2 Interventional

Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia

NCT01841723
View directory record Official record
Conditions
Hairy Cell Leukemia, Hairy Cell Leukemia Variant, Recurrent Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia Variant
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Ibrutinib, Ultrasound Imaging
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2029
U.S. locations
5
States / cities
Bethesda, Maryland • Detroit, Michigan • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 24, 2026, 6:21 PM EDT